source
- FDA flags potential VEGF-related safety concern in Summit rejection letterThe FDA flagged a safety issue in its review of Summit Therapeutics’ and Akeso's now-rejected cancer drug ivonescimab, raising questions about the viability of the whole class of new bispecifics, t…Endpoints · 40m ago↗ source
- Beren wins FDA approval for long-studied rare disease drugA molecule designed by government scientists more than a decade ago has won FDA approval to treat infantile-onset Niemann-Pick disease type C, capping a winding and rocky development path. Beren Th…Endpoints · 50m ago↗ source
- Lilly pens another deal, inking up to $5.9B oncology pact with StippleA licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio.